Nivolumab Plus Neoadjuvant Chemoradiation Fails to Enhance pCR Rate in Esophageal ...
The ECOG-ACRIN EA2174 trial did not show improved pathologic complete response (pCR) rates with nivolumab added to neoadjuvant chemoradiation for locoregional esophageal and gastroesophageal junction adenocarcinoma, compared to chemoradiation alone. The pCR rates were 24.8% with nivolumab vs 21.0% without, not statistically significant. No additional toxicity was observed, and dropout rates after surgery were high in both arms, suggesting the need for improved trial designs.
Related Clinical Trials
Reference News
The ECOG-ACRIN EA2174 trial did not show improved pathologic complete response (pCR) rates with nivolumab added to neoadjuvant chemoradiation for locoregional esophageal and gastroesophageal junction adenocarcinoma, compared to chemoradiation alone. The pCR rates were 24.8% with nivolumab vs 21.0% without, not statistically significant. No additional toxicity was observed, and dropout rates after surgery were high in both arms, suggesting the need for improved trial designs.